Quantinno Capital Management LP Purchases 26,418 Shares of Astrana Health, Inc. $ASTH

Quantinno Capital Management LP grew its position in Astrana Health, Inc. (NASDAQ:ASTH) by 69.4% in the 1st quarter, HoldingsChannel.com reports. The firm owned 64,509 shares of the company’s stock after purchasing an additional 26,418 shares during the period. Quantinno Capital Management LP’s holdings in Astrana Health were worth $1,582,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. 325 Capital LLC boosted its holdings in Astrana Health by 54.0% during the fourth quarter. 325 Capital LLC now owns 1,839,076 shares of the company’s stock worth $45,627,000 after purchasing an additional 645,123 shares during the last quarter. Wellington Management Group LLP grew its position in Astrana Health by 418.3% in the 4th quarter. Wellington Management Group LLP now owns 738,853 shares of the company’s stock worth $18,331,000 after purchasing an additional 596,293 shares in the last quarter. Ameriprise Financial Inc. increased its stake in Astrana Health by 231.0% in the 3rd quarter. Ameriprise Financial Inc. now owns 442,314 shares of the company’s stock valued at $12,540,000 after buying an additional 308,665 shares during the last quarter. Earnest Partners LLC purchased a new stake in Astrana Health in the 4th quarter valued at about $4,850,000. Finally, 1492 Capital Management LLC bought a new position in shares of Astrana Health during the 4th quarter worth approximately $4,162,000. Hedge funds and other institutional investors own 52.77% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on ASTH shares. Weiss Ratings upgraded Astrana Health from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, June 1st. Wall Street Zen upgraded Astrana Health from a “hold” rating to a “buy” rating in a report on Saturday, August 8th. Truist Financial lifted their price target on Astrana Health from $47.00 to $55.00 and gave the stock a “buy” rating in a report on Monday. Needham & Company LLC boosted their price objective on Astrana Health from $30.00 to $41.00 and gave the stock a “buy” rating in a research report on Friday, May 8th. Finally, BTIG Research upped their price objective on Astrana Health from $50.00 to $65.00 and gave the company a “buy” rating in a research note on Tuesday, July 14th. Seven analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, Astrana Health currently has an average rating of “Moderate Buy” and an average price target of $49.43.

Astrana Health Stock Up 3.8%

ASTH opened at $35.79 on Thursday. The company has a quick ratio of 1.35, a current ratio of 1.23 and a debt-to-equity ratio of 1.05. The stock has a market cap of $1.99 billion, a price-to-earnings ratio of 43.65 and a beta of 0.87. Astrana Health, Inc. has a twelve month low of $18.08 and a twelve month high of $51.60. The company’s 50-day moving average price is $41.29 and its two-hundred day moving average price is $32.70.

About Astrana Health

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients. It offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans.